TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33503527

Group type: EXPERIMENTAL
Intervention: Periodized exercise training (MSPER)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Classic endurance training (MSCLA)
Number of subjects: 31
Study: 35564687

Group type: EXPERIMENTAL
Intervention: Focused-Attention Meditation (FAM) training for 8 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (waiting list, no intervention)
Number of subjects: 140
Study: 611775172

Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anesthetic (20 mL 0.25% or 0.125% bupivacaine)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control (20 mL 0.9% NaCl)
Number of subjects: 184
Study: 35724745

Group type: EXPERIMENTAL
Intervention: Itrīfal Shāhtra (oral) and Marham Ḥina (topical)
Number of subjects: 66

Group type: COMPARATOR
Intervention: PUVAsol (oral) and petrolatum (topical)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Itrīfal Shāhtra and Marham Ḥina
Number of subjects: 66
Study: 34153715

Group type: EXPERIMENTAL
Intervention: lapatinib-trastuzumab
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: TILs
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Luminal-A subtype
Number of subjects: 121
Study: 34082392

Group type: EXPERIMENTAL
Intervention: Muscle energy techniques (METs) combined with Swedish massage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Swedish massage alone
Number of subjects: 40
Study: 32416008

Group type: EXPERIMENTAL
Intervention: Active treatment arms from CARE-HD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo data from CARE-HD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease burden score (a product of age and expanded CAG length)
Number of subjects: 0
Study: 34568050

Group type: EXPERIMENTAL
Intervention: Uterine manipulator (arm B)
Number of subjects: 154

Group type: COMPARATOR
Intervention: No uterine manipulator (arm A)
Number of subjects: 154
Study: 33197570

Group type: EXPERIMENTAL
Intervention: Mind Sound Resonance Technique (MSRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supine Rest (SR)
Number of subjects: 60
Study: 33261633

Group type: EXPERIMENTAL
Intervention: Neurocryostimulation (NCS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Traditional ice application
Number of subjects: 41
Study: 36476502

Group type: EXPERIMENTAL
Intervention: Goldilocks Work intervention (GoldiCare)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (normal work schedule)
Number of subjects: 11
Study: 33571946

Group type: EXPERIMENTAL
Intervention: sc IFN β‐1a (22 or 44 μg, three-times-weekly)
Number of subjects: 367
Study: 32150701

Group type: EXPERIMENTAL
Intervention: Cooling garment infused with 18 °C water during exercise sessions.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no cooling) during exercise sessions.
Number of subjects: 12
Study: 33687748

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Insulin degludec 100 U/mL (IDeg‐100)
Number of subjects: 596
Study: 33378433

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections with CaCl2 activating solution
Number of subjects: 16

Group type: COMPARATOR
Intervention: CaCl2 injection only (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both PRP and CaCl2 injections
Number of subjects: 16
Study: 34864554

Group type: EXPERIMENTAL
Intervention: Text-delivered mHealth intervention targeting adolescent depression and anxiety
Number of subjects: 0
Study: 33709271

Group type: EXPERIMENTAL
Intervention: PRG with gastropexy
Number of subjects: 60

Group type: COMPARATOR
Intervention: PRG without gastropexy
Number of subjects: 60
Study: 32334332

Group type: EXPERIMENTAL
Intervention: Active a-tDCS (1 mA, 20 min, for five consecutive days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Active a-tDCS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham a-tDCS
Number of subjects: 32
Study: 35511454

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) + RT + TMZ
Number of subjects: 716

Group type: COMPARATOR
Intervention: Placebo (PBO) + RT + TMZ
Number of subjects: 716
Study: 34520538

Group type: EXPERIMENTAL
Intervention: Flowable bulk-fill and microhybrid resin composites (XST)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional microhybrid resin composite (PA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Flowable bulk-fill and nanoparticulate resin composites (ABF)
Number of subjects: 53
Study: 34775810

Group type: EXPERIMENTAL
Intervention: Video follow-up visits
Number of subjects: 24

Group type: COMPARATOR
Intervention: In-person follow-up visits
Number of subjects: 24
Study: 33629461

Group type: EXPERIMENTAL
Intervention: biphasic calcium phosphate covered by a cross‐linked collagen membrane (test group)
Number of subjects: 8

Group type: COMPARATOR
Intervention: deproteinized bovine bone mineral covered by a natural collagen membrane (positive control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: no treatment (negative control)
Number of subjects: 8
Study: 36121669

Group type: EXPERIMENTAL
Intervention: Crenezumab (60 mg/kg intravenously every 4 weeks for up to 100 weeks)
Number of subjects: 1619

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1619

Group type: EXPERIMENTAL
Intervention: Crenezumab
Number of subjects: 1619
Study: 33833224

Group type: COMPARATOR
Intervention: GnRH agonist (Lupron)‐induced ovarian suppression
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Estradiol add‐back
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Progesterone add‐back
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lupron alone to progesterone conditions
Number of subjects: 63
Study: 35555329

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB) therapy (amlodipine)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CCB + ACE inhibitor therapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CCB + ACE inhibitor + decreased salt intake
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: All antihypertensive therapies
Number of subjects: 140
Study: 32586396

Group type: EXPERIMENTAL
Intervention: CytoSorb therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study: 35896261

Group type: EXPERIMENTAL
Intervention: Oral Vitamin B12 500 μg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Oral Vitamin B12 1,500 μg/day
Number of subjects: 74
Study: 33549074

Group type: EXPERIMENTAL
Intervention: Wood dust exposure
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Past occupational dust exposure history
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Work experience > 5 years
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Using bio-fuel as energy for cooking
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: No occupational safety and health training
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Personal wood dust exposure level
Number of subjects: 506
Study: 36456016

Group type: EXPERIMENTAL
Intervention: 2 g of oral azithromycin
Number of subjects: 2110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2110
Study: 34922212

Group type: EXPERIMENTAL
Intervention: Unambiguous person-derived reassurance information
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Unambiguous object-derived checking information
Number of subjects: 398

Group type: COMPARATOR
Intervention: Ambiguous person-derived reassurance information
Number of subjects: 398

Group type: COMPARATOR
Intervention: Ambiguous object-derived checking information
Number of subjects: 398
Study: 34787873

Group type: EXPERIMENTAL
Intervention: Prehabilitation program (physical training, nutritional and lifestyle counseling)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 14
Study: 33166308

Group type: EXPERIMENTAL
Intervention: Percutaneous repair (PR) using Mitra‐Fr data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Percutaneous repair (PR) using Coapt data
Number of subjects: 0
Study: 36070450

Group type: EXPERIMENTAL
Intervention: iTind (temporarily implanted nitinol device)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 185
Study: 34013428

Group type: EXPERIMENTAL
Intervention: uniportal video‐assisted thoracoscopic surgery (uni‐VATS)
Number of subjects: 84

Group type: COMPARATOR
Intervention: conventional 3‐port video‐assisted thoracoscopic surgery (3-port VATS)
Number of subjects: 84
Study: 32795739

Group type: EXPERIMENTAL
Intervention: Lysulin™
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 33766702

Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling every 2 weeks during therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intervention group (nutritional counseling)
Number of subjects: 61
Study: 32631586

Group type: EXPERIMENTAL
Intervention: estradiol 1 mg combined with drospirenone 2 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 32908086

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 640

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 640
Study: 33836635

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) and histone deacetylase inhibitors (HDACi) combination
Number of subjects: 0
Study: 32930040

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for chronic fatigue syndrome
Number of subjects: 995
Study: 33630043

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 312

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 312
Study: 32419647

Group type: EXPERIMENTAL
Intervention: High worry condition
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Low worry condition
Number of subjects: 804

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 804
Study: 616120483

Group type: EXPERIMENTAL
Intervention: Refresh Contacts
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Systane Balance
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Optive Plus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All products tested (Optive Plus, Refresh Contacts, Systane Balance)
Number of subjects: 18
Study: 33407248

Group type: EXPERIMENTAL
Intervention: Interventions for outdoor exposure reduction
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Interventions for both outdoor and indoor exposure reduction
Number of subjects: 211

Group type: COMPARATOR
Intervention: No intervention for desert dust events
Number of subjects: 211
Study: 33136831

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 651
Study: 33234323

Group type: EXPERIMENTAL
Intervention: Visuomotor therapy (active)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive motion (sham)
Number of subjects: 10
Study: 34362348

Group type: EXPERIMENTAL
Intervention: Bipolar coagulation forceps
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 177
Study: 35686576

Group type: EXPERIMENTAL
Intervention: Interdisciplinary graded exposure treatment (GET Living)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Multidisciplinary pain management (Control)
Number of subjects: 68
Study: 32989170

Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptives (COC) (Triphasil or Nordette)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Injectable Norethisterone Enanthate (Net-En)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Combined Contraceptive Vaginal Ring (CCVR; NuvaRing)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Combined Oral Contraceptives (COC)
Number of subjects: 130
Study: 36480272

Group type: EXPERIMENTAL
Intervention: In-person coaching
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Virtual coaching
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control
Number of subjects: 224
Study: 33596989

Group type: EXPERIMENTAL
Intervention: Significant unexplained indirect hyperbilirubinemia (cases)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no significant unexplained indirect hyperbilirubinemia)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cases with UTI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: UTI positive patients
Number of subjects: 150
Study: 32634745

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 34514653

Group type: EXPERIMENTAL
Intervention: Earplugs
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Eye masks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Eye masks with earplugs
Number of subjects: 68
Study: 33481828

Group type: EXPERIMENTAL
Intervention: Prism adaptation treatment (PAT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment (active control)
Number of subjects: 34
Study: 32067836

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure intervention
Number of subjects: 8052

Group type: COMPARATOR
Intervention: Standard blood pressure intervention
Number of subjects: 8052
Study: 36054480

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily)
Number of subjects: 5661

Group type: COMPARATOR
Intervention: Ramipril (5 mg twice daily)
Number of subjects: 5661

Group type: COMPARATOR
Intervention: Sensitivity analysis for events meeting CEC definitions
Number of subjects: 5661
Study: 33647529

Group type: EXPERIMENTAL
Intervention: Regulated BFRT (Delfi's Personalized Tourniquet System) at 30% 1RM
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Standardized BFRT (B-Strong™ device) at 30% 1RM
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-load resistance exercise at 80% 1RM
Number of subjects: 34
Study: 35543939

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Siguan points (Hegu [LI 4] and Taichong [LR 3]), 30 min each time, once a day, 5 times per week for 4 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Flunarizine hydrochloride capsule, 10 mg a day for 4 weeks
Number of subjects: 110
Study: 33239872

Group type: EXPERIMENTAL
Intervention: New Endurance Test (ET) starting at 75% of WMAX, increasing stepwise by 3% every 2 minutes until exhaustion (Study A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: New Endurance Test (ET) starting at 70% of WMAX, increasing linearly by 1% per minute (Study B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard Endurance Test (ET)
Number of subjects: 33
Study: 35947864

Group type: EXPERIMENTAL
Intervention: Brief Solution Focused Therapy (BSFT), 5 sessions over 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care for schizophrenia
Number of subjects: 30
Study: 34432011

Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 107
Study: 32933504

Group type: COMPARATOR
Intervention: Febuxostat 40 mg once daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Terminalia bellerica (TBE) 500 mg twice daily
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Terminalia bellerica (TBE) 1000 mg twice daily
Number of subjects: 59
Study: 35417958

Group type: EXPERIMENTAL
Intervention: Iron therapy (1000 mg ferric carboxymaltose in 100 mL saline, infused slowly over 15 min 7 days before surgery)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Iron therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (100 mL saline, infused slowly over 15 min 7 days before surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33493160

Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Active control group (aCG)
Number of subjects: 66
Study: 32298023

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided aspiration
Number of subjects: 156
Study: 35263434

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine plus amiodarone
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo plus amiodarone
Number of subjects: 154
Study: 33823738

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trimetazidine
Number of subjects: 60
Study: 32587723

Group type: EXPERIMENTAL
Intervention: Foot-care educational programme with foot-care tools, 3-5 sessions over 2 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Foot-care educational programme
Number of subjects: 110
Study: 34579112

Group type: EXPERIMENTAL
Intervention: Inulin (10 g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 10 g/day)
Number of subjects: 24
Study: 33163534

Group type: EXPERIMENTAL
Intervention: Mobile video call‐guided
Number of subjects: 90

Group type: COMPARATOR
Intervention: Voice call‐guided
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non‐guided
Number of subjects: 90
Study: 36065810

Group type: EXPERIMENTAL
Intervention: Low-dose nelonemdaz (2750 mg)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: High-dose nelonemdaz (5250 mg)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 34391264

Group type: EXPERIMENTAL
Intervention: Knitting program (8-week duration) with bi-weekly 20-min group sessions and daily 20-min home sessions
Number of subjects: 37

Group type: COMPARATOR
Intervention: Educational pamphlet (control group)
Number of subjects: 37
Study: 32592693

Group type: EXPERIMENTAL
Intervention: Physical examination‐indicated cerclage
Number of subjects: 34
Study: 35507508

Group type: EXPERIMENTAL
Intervention: CoVLP+AS03 vaccine
Number of subjects: 24141
Study: 34950944

Group type: EXPERIMENTAL
Intervention: Intensive screening (home tracing and intensive HIV/TB screening)
Number of subjects: 4459

Group type: COMPARATOR
Intervention: Standard of care (SOC, clinic referral letters)
Number of subjects: 4459

Group type: EXPERIMENTAL
Intervention: Intensive screening
Number of subjects: 4459

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 4459
Study: 36100263

Group type: EXPERIMENTAL
Intervention: Extended duration thromboprophylaxis using daily subcutaneous tinzaparin at 4500 IU for 56 days postoperatively
Number of subjects: 614

Group type: COMPARATOR
Intervention: In-hospital postoperative thromboprophylaxis only
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Extended duration thromboprophylaxis using daily subcutaneous tinzaparin at 4500 IU
Number of subjects: 614
Study: 34170798

Group type: EXPERIMENTAL
Intervention: Multicomponent nursing intervention program focusing on modifiable risk factors
Number of subjects: 1749

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1749

Group type: EXPERIMENTAL
Intervention: Multicomponent nursing intervention program
Number of subjects: 1749
Study: 33230290

Group type: EXPERIMENTAL
Intervention: Placebo delivered by VEx
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: No-treatment delivered by VEx
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo delivered by text-only control
Number of subjects: 54

Group type: COMPARATOR
Intervention: No-treatment delivered by text-only control
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Expectancy manipulation (placebo or no-treatment)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: VEx regardless of treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Secondary analyses
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Retrospective pain ratings
Number of subjects: 54
Study: 35564596

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (two doses of IM dexamethasone 12 mg, 12 hours apart, 24 hours prior to surgery)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 189
Study: 33526149

Group type: EXPERIMENTAL
Intervention: Patient Support Programs (PSPs) awareness
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Reason for nonadherence
Number of subjects: 385
Study: 32086819

Group type: EXPERIMENTAL
Intervention: Eculizumab (single infusion)
Number of subjects: 10
Study: 33782926

Group type: EXPERIMENTAL
Intervention: Cold endoscopic mucosal resection (EMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hot endoscopic mucosal resection (EMR)
Number of subjects: 0
Study: 33474955

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 106

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 106
Study: 34807716

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (third dose)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 32690203

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Phone delivery by a trained navigator
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Web + Phone intervention
Number of subjects: 692

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 692
Study: 36343880

Group type: EXPERIMENTAL
Intervention: Group-based Family-Based Treatment (FBT)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Guided self-help Family-Based Treatment (gshFBT)
Number of subjects: 150
Study: 33402353

Group type: EXPERIMENTAL
Intervention: Ironbark: Standing Strong and Tall programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Community programme
Number of subjects: 0
Study: 32371430

Group type: EXPERIMENTAL
Intervention: FKB327
Number of subjects: 728

Group type: COMPARATOR
Intervention: Adalimumab reference product (RP)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: FKB327 or RP (with treatment switching)
Number of subjects: 728
Study: 35552824

Group type: EXPERIMENTAL
Intervention: Oxabact (lyophilized O. formigenes formulation), administered orally, twice daily for 52 weeks.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo, administered orally, twice daily for 52 weeks.
Number of subjects: 25
Study: 32909168

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT
Number of subjects: 187
Study: 32314971

Group type: EXPERIMENTAL
Intervention: WeChat official account (Pulmonary Internet Explorer Rehabilitation [PeR])
Number of subjects: 106

Group type: COMPARATOR
Intervention: Outpatient face‐to‐face group (FtF)
Number of subjects: 106
Study: 35350970

Group type: EXPERIMENTAL
Intervention: START-Play physical therapy intervention
Number of subjects: 112